If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.

Many devices in current use were marketed before manufacturers were required to demonstrate safety and effectiveness.

Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"

Current QoL conversations in HTx could be enhanced by a phenomenological account of temporality, embodiment, and intersubjectivity.

Considering chronic opioid use when planning elective surgery would likely enhance team communication, decrease stigma, and facilitate care transitioning and long-term planning.